Top Markets
#1 Pleasing Gold Pleasing Gold +1,548.36%
#2 PulseChain PulseChain +58.48%
#3 Merlin's Seal BTC Merlin's Seal BTC +32.56%
#4 Ontology Gas Ontology Gas +32.42%
#5 BOOK OF MEME BOOK OF MEME +30.49%
#6 Pump.fun Pump.fun +24.97%
#7 Unit Pump Unit Pump +24.97%
#8 Nockchain Nockchain +21.96%
#9 RSK Infrastructure Framework RSK Infrastructure Framework +21.19%
#10 Neiro Neiro +19.16%
Coin of the day
Pleasing Gold Pleasing Gold
Settings
Language
ENGLISH
Currency
USD
Theme
Navamedic ASA Navamedic ASA

Navamedic ASA

NAVA
Rank in Stocks #26770
Navamedic ASA, an Oslo, Norway-based pharmaceutical firm established in 2002... Navamedic ASA, an Oslo, Norway-based pharmaceutical firm established in 2002 and formerly known as Glucomed AS until its name change in 2004, operates across Northern Europe. The company is actively involved in the entire lifecycle of pharmaceutical and related goods, from development and manufacturing to their commercialization and distribution. Its comprehensive portfolio encompasses a diverse range of products, including prescribed and over-the-counter medications, specialized medical nutrition, medical devices, dietary supplements, and cosmetic items. A significant portion of its offerings is dedicated to medical nutrition, formulated to address various metabolic disorders such as phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia, methylmalonic acidemia/propionic acidemia, glutaric aciduria, isovaleric acidemia, and urea cycle disorders. These nutritional solutions also cater to conditions like glycogen storage diseases, renal diseases, fat metabolism issues, malnutrition, and support for ketogenic diets. Furthermore, Navamedic features a consumer health division providing non-prescription drugs and wellness products for common ailments including pain relief, coughs, colds, gastrointestinal issues, and women's health, primarily distributed through pharmacies and drugstores. The company also supplies specialty pharmaceuticals targeting specific therapeutic areas such as dermatology, wound care, women's health, urology, and obesity. Completing its product line are branded generics, notably in cardiology and antibiotics. Its widespread distribution network ensures products reach hospitals, individual patients, and retail pharmacies throughout its operational regions.
Share Price
$1.60
Market Cap
$38.33M
Change (1 day)
-3.17%
Change (1 year)
-27.00%
Country
NO
Trade Navamedic ASA (NAVA)

Category

Healthcare
P/E ratio for Navamedic ASA (NAVA)
P/E ratio as of 2026 TTM: 0
According to Navamedic ASA latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Navamedic ASA from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
McKesson Corporation McKesson Corporation
McKesson Corporation
MCK.US
 23.15 -
US
Cencora, Inc. Cencora, Inc.
Cencora, Inc.
COR.US
 - -
US
Cardinal Health, Inc. Cardinal Health, Inc.
Cardinal Health, Inc.
CAH.US
 32.35 -
US
AmerisourceBergen Corporation AmerisourceBergen Corporation
AmerisourceBergen Corporation
ABC.US
 - -
US
Sigma Healthcare Limited Sigma Healthcare Limited
Sigma Healthcare Limited
SIG.AX
 -338.64 -
AU
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.